Document Detail

Urinary proteomics for prediction of preeclampsia.
MedLine Citation:
PMID:  21199994     Owner:  NLM     Status:  MEDLINE    
Preeclampsia is a major determinant of fetal and maternal morbidity and mortality. We used a proteomic strategy to identify urinary biomarkers that predict preeclampsia before the onset of disease. We prospectively collected urine samples from women throughout pregnancy. Samples from gestational weeks 12 to 16 (n=45), 20 (n=50), and 28 (n=18) from women who subsequently had preeclampsia develop were matched to controls (n=86, n=49, and n=17, respectively). We performed capillary electrophoresis online coupled to micro-time-of-flight mass spectrometry. Disease-specific peptide patterns were generated using support vector machine-based software. Candidate biomarkers were sequenced by liquid chromatography-tandem mass spectrometry. From comparison with nonpregnant controls, we defined a panel of 284 pregnancy-specific proteomic biomarkers. Subsequently, we developed a model of 50 biomarkers from specimens obtained at week 28 that was associated with future preeclampsia (classification factor in cases, 1.032 ± 0.411 vs controls, -1.038 ± 0.432; P<0.001). Classification factor increased markedly from week 12 to 16 to 28 in women who subsequently had preeclampsia develop (n=16; from -0.392 ± 0.383 to 1.070 ± 0.383; P<0.001) and decreased slightly in controls (n=16; from -0.647 ± 0.437 to -1.024 ± 0.433; P=0.043). Among the biomarkers are fibrinogen alpha chain, collagen alpha chain, and uromodulin fragments. The markers appear to predict preeclampsia at gestational week 28 with good confidence but not reliably at earlier time points (weeks 12-16 and 20). After prospective validation in other cohorts, these markers may contribute to better prediction, monitoring, and accurate diagnosis of preeclampsia.
David M Carty; Justyna Siwy; Janet E Brennand; Petra Zürbig; William Mullen; Julia Franke; James W McCulloch; Claire T Roberts; Robyn A North; Lucy C Chappell; Harald Mischak; Lucilla Poston; Anna F Dominiczak; Christian Delles
Related Documents :
15695314 - What is the 'ideal' duration of progesterone supplementation before the transfer of cry...
21258054 - Carbimazole embryopathy: implications for the choice of antithyroid drugs in pregnancy.
21458814 - Prenatal diagnostic rates and postnatal outcomes of fetal orofacial clefts in a taiwane...
7829994 - Maternal plasma levels of human chorionic gonadotrophin, oestradiol and progesterone in...
11239654 - Prenatal diagnosis of congenital cytomegalovirus infection.
23680224 - Efficacy of dehydroepiandrosterone to improve ovarian response in women with diminished...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2011-01-03
Journal Detail:
Title:  Hypertension     Volume:  57     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-02-17     Completed Date:  2011-04-14     Revised Date:  2011-10-25    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  561-9     Citation Subset:  IM    
Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary, and Life Sciences, University of Glasgow, Glasgow, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / analysis,  urine
Chromatography, Liquid
Mass Spectrometry
Pre-Eclampsia / diagnosis*,  urine*
Predictive Value of Tests
Grant Support
RG/07/005/23633//British Heart Foundation
Reg. No./Substance:
0/Biological Markers
Erratum In:
Hypertension. 2011 Oct;58(4):e32
Note: Roberts, Claire T [added]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Angiotensin II regulates adrenal vascular tone through zona glomerulosa cell-derived EETs and DHETs.
Next Document:  Detecting sodium-sensitivity in hypertensive patients: information from 24-hour ambulatory blood pre...